Description: Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Home Page: cgen.com
CGEN Technical Analysis
Azrieli Center
Holon,
5885849
Israel
Phone:
972 3 765 8585
Officers
Name | Title |
---|---|
Dr. Anat Cohen-Dayag Ph.D. | CEO, Pres & Director |
Dr. Oliver Froescheis Ph.D. | Sr. VP of Corp. & Bus. Devel. |
Dr. Zurit Levine | Sr. VP of Technology Innovation |
Dr. Henry Adewoye M.D. | Sr. VP & Chief Medical Officer |
Mr. Alberto Sessa | Chief Financial Officer |
Ms. Yvonne Naughton | Head of Investor Relations & Corp. Communications |
Mr. Eran Ben Dor | Gen. Counsel & Corp. Sec. |
Ms. Dorit Amitay | VP of HR |
Dr. Yaron Turpaz M.B.A., Ph.D., MBA | Sr. VP & Sr. Advisor of Computational Discovery |
Rivka Schwartz | VP Research and Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.0019 |
Price-to-Sales TTM: | 12.8941 |
IPO Date: | 2000-08-11 |
Fiscal Year End: | December |
Full Time Employees: | 73 |